<SEC-DOCUMENT>0000318154-23-000026.txt : 20230427
<SEC-HEADER>0000318154-23-000026.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427161158
ACCESSION NUMBER:		0000318154-23-000026
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230427
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		23856976

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>amgn-20230427.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:fa651973-2c88-43d0-a2e8-806f3a520803,g:a19d5020-bb4e-4934-9fa2-38cf90db5df6,d:1d2e6961e3e94f0a8de7ae829161a876--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:amgn="http://www.amgen.com/20230427" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20230427</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl80L2ZyYWc6MDczMWQ3Y2EyMjcyNDhiMTg2ZjA1ZjBjOWEwMDUxZjAvdGFibGU6ZmQzZTEwYWZmOGJiNGZmMWIwZTYyMzc2MmM5YjA1YTYvdGFibGVyYW5nZTpmZDNlMTBhZmY4YmI0ZmYxYjBlNjIzNzYyYzliMDVhNl8zLTEtMS0xLTIyNTY3OQ_fc06d8f7-f7cb-4075-b3d0-2e825e193aca">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl80L2ZyYWc6MDczMWQ3Y2EyMjcyNDhiMTg2ZjA1ZjBjOWEwMDUxZjAvdGFibGU6ZmQzZTEwYWZmOGJiNGZmMWIwZTYyMzc2MmM5YjA1YTYvdGFibGVyYW5nZTpmZDNlMTBhZmY4YmI0ZmYxYjBlNjIzNzYyYzliMDVhNl80LTEtMS0xLTIyNTY3OQ_561d5a39-d922-49a2-8283-e9ba1f46fd47">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20230427.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1d2e6961e3e94f0a8de7ae829161a876_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTE5_6116eeb3-217a-4870-b5d4-b63487791514">8-K</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 OR 15(d) of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8yMjg_5fd16a89-0716-46f7-b3e8-9ce4551bd230">April&#160;27, 2023</ix:nonNumeric></span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;-</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTIx_94002c5d-1c52-4d85-8adc-6ac54fa8350c">Amgen Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8wLTAtMS0xLTIyNTY3OQ_6a1bf2e1-3050-4000-95e2-6ddaef1e5adb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8wLTItMS0xLTIyNTY3OQ_fcb9b1e9-680e-4559-980f-479c50b3d7e1">001-37702</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8wLTQtMS0xLTIyNTY3OQ_f056487b-5b99-415c-b573-da56038b402c">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8zLTAtMS0xLTIyNTY3OQ_35991dbe-aa24-422e-ae3a-9fc7a9b27ca6">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV80LTAtMS0xLTIyNTY3OQ_8f71aa4e-11f9-417e-ba99-b83772a0ba1c">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV81LTAtMS0xLTIyNTY3OQ_4da6cfeb-5709-4c14-a4e1-7074e3b276e2">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV81LTQtMS0xLTIyNTY3OQ_f307a9d5-1cfc-4d1b-aa86-5a82161beda6">91320-1799</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTIy_263caf4d-9330-400c-806c-c7cc96a2ae22">805</ix:nonNumeric>) <ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTE3_04dc098c-9917-4b61-9c6d-f494ca6dd56c">447-1000</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6MzFkN2VjY2E4ZGE3NDQ4MGExOTBjMDJiMDc4YTY2MjMvdGFibGVyYW5nZTozMWQ3ZWNjYThkYTc0NDgwYTE5MGMwMmIwNzhhNjYyM18wLTAtMS0xLTIyNTY3OQ_2f8ee7fb-28c0-4ddd-ad5b-d762471249a8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6OWYxODRjZTdhMDg4NDliY2E2YjY0ZWNkM2Q2NGI2ZTkvdGFibGVyYW5nZTo5ZjE4NGNlN2EwODg0OWJjYTZiNjRlY2QzZDY0YjZlOV8wLTAtMS0xLTIyNTY3OQ_a045af4b-08c4-4f48-8b92-fd42fd178a29">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6NGUwMGM5YzUyOGUzNDVlMTlkM2EyYjA0ZGMyOTMzNDEvdGFibGVyYW5nZTo0ZTAwYzljNTI4ZTM0NWUxOWQzYTJiMDRkYzI5MzM0MV8wLTAtMS0xLTIyNTY3OQ_35494919-ea96-4f74-8e7c-12d3e9c19bce">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6NDUwYTFlY2JmZDRmNDdkY2JjZDZhNDAzODE0ZjVhZjUvdGFibGVyYW5nZTo0NTBhMWVjYmZkNGY0N2RjYmNkNmE0MDM4MTRmNWFmNV8wLTAtMS0xLTIyNTY3OQ_92c08aaf-2905-40b8-ae41-1d5b622d0d7e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8xLTAtMS0xLTIyNTY3OQ_3b40c6c5-5804-49a8-968b-92d46251f651">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8xLTEtMS0xLTIyNTY3OQ_a86404f6-6d36-4ebb-87ae-f5ecad030ef6">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8xLTItMS0xLTIyNTY3OQ_919bd774-a60b-4278-9f29-f1db134a7b03">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8yLTAtMS0xLTIyNTY3OQ_ff742b5e-d35b-4b99-82e2-3a1b2136d717">2.000% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8yLTEtMS0xLTIyNTY3OQ_8400ab10-9988-4ed5-8b32-00c4baf5199a">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8yLTItMS0xLTIyNTY3OQ_ebf8cafa-4104-4c70-b664-0b346e6e19e8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTE4_1a09fb3a-8b47-4494-9633-75196a3b221c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1.5pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i1d2e6961e3e94f0a8de7ae829161a876_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xMC9mcmFnOjVlYTY1YmI4NDhkNDQyMjE5ZjhlZTA2M2I4MGY5NzA2L3RleHRyZWdpb246NWVhNjViYjg0OGQ0NDIyMTlmOGVlMDYzYjgwZjk3MDZfNTQ5NzU1ODI2MTk4_5fd16a89-0716-46f7-b3e8-9ce4551bd230">April&#160;27, 2023</ix:nonNumeric>, the Company issued a press release announcing its unaudited results of operations for the three months ended March 31, 2023, and its unaudited financial position as of March 31, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, non-GAAP other income (expense), net, non-GAAP interest expense, net, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development (R&amp;D) expenses and non-GAAP selling, general and administrative expenses. Reconciliations for such non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the press release. The Company included Free Cash Flow (FCF), which is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. The Company also included Total Revenues and Product Sales Adjusted for Foreign Exchange Impact, which is computed by converting our current period local currency product sales using the prior period foreign exchange rates and comparing that to our current period product sales. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that this presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity. The Company believes that Total Revenues and Product Sales Adjusted for Foreign Exchange Impact provides supplementary information on the Company's product sales performance by excluding changes in foreign exchange rates between comparative periods. The Company uses non-GAAP financial measures in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the costs and other items excluded from the most directly comparable GAAP financial measures to calculate non-GAAP financial measures:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Acquisition-related expenses: Acquisition-related charges are primarily associated with intangible assets acquired in connection with business acquisitions. Such charges include amortization of developed-product-technology rights, licensing rights, R&amp;D technology rights, and marketing-related rights, as well as impairments of in-process R&amp;D assets. Charges for purchased intangible assets are significantly impacted by the timing and magnitude of the Company&#8217;s acquisitions and potential product approvals as they relate to in-process R&amp;D projects acquired. Accordingly, these charges may vary in amount from period to period. The Company excludes these charges for purposes of calculating the non-GAAP financial measures presented to facilitate a more meaningful evaluation of the Company&#8217;s current operating performance and comparisons to past operating performance. The Company believes that excluding the noncash charges related to those intangible assets acquired in business acquisitions treats those assets as if the Company had developed them internally in the past and, thus, provides a supplemental measure of profitability in which the Company&#8217;s acquired intellectual property is treated in a comparable manner to its internally-developed-intellectual property.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Net charges pursuant to the Company&#8217;s restructuring and costs savings initiatives: Costs from restructuring and cost savings initiatives are primarily related to facilities charges, including accelerated depreciation, and severance and benefits for employees terminated pursuant to our transformation and process improvement efforts. Costs from such initiatives are inconsistent in amount and are significantly impacted by the timing and nature of these events. Therefore, although the Company may incur these types of expenses in the future, it believes that eliminating these charges for purposes of calculating the non-GAAP financial measures provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Other items: The Company adjusts GAAP financial results for certain income and expenses (or gains and losses). These adjustments include (1) certain items from investment transactions, including amortization and impairments from the basis difference that arises from certain equity method investments and certain gains and losses on our investments in equity securities that are recorded to other income and expense; (2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the impact of nonstrategic divestitures, which includes cumulative foreign currency translation adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (3) certain items associated with judgments and/or settlements for legal proceedings discussed in our filings; and (4) (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit agreement and term loan credit agreement, incurred prior to the closing of our proposed acquisition of Horizon Therapeutics plc. The Company excludes these items for the purpose of calculating the non-GAAP financial measures presented because the Company believes these items are outside the ordinary course of business. The Company believes eliminating these items provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The tax effect of the adjustments between GAAP and non-GAAP results take into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets, whereas the tax impact of other adjustments, including expenses related to restructuring and cost savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The press release also contains a discussion of the additional purposes for which the Company&#8217;s management uses these non-GAAP financial measures. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information and the information contained in the press release shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i1d2e6961e3e94f0a8de7ae829161a876_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-2023331earningsrelease.htm">Press Release dated April 27, 2023</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i1d2e6961e3e94f0a8de7ae829161a876_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">April 27, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>amgn-2023331earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibc30363960d242a083f5a53e4ab02fe6_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><img alt="amgenlogoa14.jpg" src="amgenlogoa14.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:100%">News Release</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">One Amgen Center Drive<br>Thousand Oaks, CA  91320-1799<br>Telephone 805-447-1000<br>www.amgen.com</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="ibc30363960d242a083f5a53e4ab02fe6_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THOUSAND OAKS, Calif. (April&#160;27, 2023) - Amgen (NASDAQ&#58;AMGN) today announced financial results for the first quarter of 2023. </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#34;We delivered 14% volume growth driven by the breadth of our portfolio and strong demand for our products globally,&#34; said Robert A. Bradway, chairman and chief executive officer. &#34;We look forward to closing the acquisition of Horizon Therapeutics and joining forces to reach more patients around the world with their innovative medicines.&#34;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Key results include&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Total revenues decreased 2% to $6.1 billion in comparison to the first quarter of 2022, resulting from lower Other Revenue from our COVID-19 manufacturing collaboration, partially offset by a 2% increase in product sales. Produ</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ct sales growth was driven by 14% volume growth, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels and 2% negative impact from foreign exchange. Excluding the 2% negative impact of foreign exchange on product sales, total revenues were largely unchanged from Q1 2022.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Volume growth of 14% included double-digit volume growth from EVENITY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (romosozumab-aqqg), BLINCYTO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (blinatumomab), Nplate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(romiplostim), LUMAKRAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;LUMYKRAS&#8482; (sotorasib), AMJEVITA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;AMGEVITA&#8482; (adalimumab), Repatha</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (evolocumab), KYPROLIS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (carfilzomib) and Vectibix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (panitumumab).  </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Ex-U.S. volume grew 22%, including 47% volume growth in the Asia Pacific region.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">GAAP earnings per share (EPS) increased 97% from $2.68 to $5.28, driven by other income due to a mark-to-market gain on our investment in BeiGene, Ltd. and lower weighted-average shares outstanding in Q1 2023. </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">GAAP operating income decreased from $2.5 billion to $1.9 billion, and GAAP operating margin decreased 10.7 percentage points to 32.9%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Non-GAAP EPS decreased 6% from $4.25 to $3.98, driven by decreased revenues and higher operating expenses, primarily related to research &#38; development, in Q1 2023.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Non-GAAP operating income decreased from $3.1 billion to $2.8 billion, and non-GAAP operating margin decreased 6.5 percentage points to 48.3%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company generated $0.7 billion of free cash flow for the first quarter of 2023 versus $2.0 billion in the first quarter of 2022, driven by the timing of payments for sales incentives, rebates and discounts, lower operating income, and higher capital expenditures from the build-out of our new North Carolina and Ohio facilities.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 2</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">References in this release to &#8220;non-GAAP&#8221; measures, measures presented &#8220;on a non-GAAP basis,&#8221; &#8220;free cash flow&#8221; (computed by subtracting capital expenditures from operating cash flow) and &#8220;total revenues and product sales adjusted for foreign exchange impact&#8221; (computed by converting our current period local currency product sales using the prior period foreign exchange rates and comparing that to our current period product sales) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.</font></div><div id="ibc30363960d242a083f5a53e4ab02fe6_7"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Performance</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Total product sales increased 2% for the first quarte</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">r of 2023 versus the first quarter of 2022. Unit volumes grew 14%, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels and 2% negative impact from foreign exchange.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">General Medicine</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">Repatha</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 18% year-over-year to a record $388 million for the first quarter. Volume growth of 33% for the quarter was partially offset by lower net selling price. In the U.S., sales grew 19%, driven by 32% volume growth, partially offset by lower net selling price and inventory levels. Outside the U.S., sales grew 16%, driven by 34% volume growth, partially offset by lower net selling price and unfavorable foreign exchange impact. Repatha remains the global proprotein convertase subtilisin&#47;kexin type 9 (PCSK9) segment leader, with over 1.7 million patients treated since launch. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">Prolia</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (denosumab) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 9% year-over-year for the first quarter, driven by 8% volume growth.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">EVENITY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 49% year-over-year to a record $254 million for the first quarter, primarily driven by strong volume growth across our markets. U.S. volumes grew 43% year-over-year and volumes outside the U.S. grew 77%.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Aimovig</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> (erenumab-aooe) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">sales decreased 32% year-over-year for the first quarter, driven by unfavorable changes to estimated sales deductions and lower net selling price. For 2023, we expect continued year-over-year net selling price declines in order to maintain broad formulary access for patients in response to competitive dynamics.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inflammation</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">TEZSPIRE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (tezepelumab-ekko)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> generated $96 million of sales in the first quarter, driven by strong adoption in the U.S. by both allergists and pulmonologists. Quarter-over-quarter sales increased 22%, driven by volume growth. Healthcare providers appreciate TEZSPIRE&#8217;s unique, differentiated profile and its broad potential to treat the 2.5 million patients worldwide with severe asthma who are uncontrolled, without any phenotypic or biomarker limitation. During the first quarter, the U.S. Food and Drug Administration (FDA) approved TEZSPIRE for self-administration in a pre-filled, single-use pen, which improves accessibility and provides more flexibility in treatment options for patients in the U.S. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">TAVNEOS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (avacopan)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> generated $23 million of sales in the first quarter. Quarter-over-quarter sales increased 10%, driven by higher net selling price and inventory levels, partially offset by lower ex-U.S. volume driven by the timing of shipments to our ex-U.S. partner in the fourth quarter of 2022. U.S volume grew 27% quarter-over-quarter, driven by an increase in new patients starting treatment.  </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 3</font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">Otezla</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (apremilast) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales decreased 13% year-over-year for the first quarter, driven by lower inventory levels and net selling price, partially offset by 5% volume growth. Otezla followed the historical pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients worked through deductibles. U.S. sales in the first quarter were also impacted by lower specialty pharmacy inventory levels compared to previous years, and price declines resulting from patient mix and additional rebates to improve the quality of coverage. In the U.S., Otezla new patient demand was impacted by free drug programs for newly launched topical and systemic competitors. We expect new patient demand to continue to be impacted by free drug programs from newly launched competition throughout 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We continue to see strong growth potential for Otezla given its established efficacy and safety profile, strong payor coverage with limited prior authorization requirements and ease of administration.  Otezla remains the only approved oral systemic therapy with a broad indication and is well-positioned to help the 1.5 million U.S. patients with mild-to-moderate psoriasis that cannot be optimally addressed by a topical and can benefit from a systemic treatment like Otezla.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">Enbrel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (etanercept) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales decreased 33% year-over-year for the first quarter, driven by decline in net selling price, lower inventory levels in the distribution channel compared to previous years and a 9% unfavorable impact of changes to estimated sales deductions related to prior periods. Consistent with Otezla, sales in the first quarter were also impacted by typical patterns of benefit plan changes and higher co-pay expenses. Year-over-year volume was flat in the first quarter, with U.S. volume growing 1%, supported by improved payor coverage. For the remainder of 2023, we expect low single-digit volume growth, reduced year-over-year decline in net selling price and a gradual recovery in inventory levels.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">AMJEVITA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#47;AMGEVITA&#8482; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 52% year-over-year to a record $164 million for the first quarter, driven by higher inventory levels and 35% volume growth, partially offset by unfavorable foreign exchange impact. AMJEVITA launched in the U.S. early in the first quarter, and a majority of U.S. sales in the quarter were related to inventory build.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Hematology-Oncology</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">BLINCYTO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 41% year-over-year to a record $194 million for the first quarter, driven by 49% volume growth supported by strong adoption across academic and community centers.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">Vectibix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 16% year-over-year for the first quarter, driven by 15% volume growth supported by positive data from the Phase 3 PARADIGM trial demonstrating the superiority of Vectibix over bevacizumab in combination with chemotherapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">KYPROLIS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 25% year-over-year to a record $358 million for the first quarter, driven by 18% volume growth, higher net selling price and strong global execution.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">LUMAKRAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#47;LUMYKRAS&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> generated $74 million of sales for the first quarter. Year-over-year sales increased 19% for the first quarter, driven by 40% volume growth, partially offset by lower net selling price. Outside the U.S., LUMYKRAS has been approved in 50 countries around the world. We are actively launching in over 30 markets and pursuing reimbursement in the remaining countries.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 4</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">XGEVA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (denosumab) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 7% year-over-year for the first quarter, driven by higher net selling price and 4% volume growth. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">Nplate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales increased 36% year-over-year for the first quarter, driven by 41% volume growth. Nplate sales in the first quarter included $82 million related to an order from the U.S. government.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">MVASI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (bevacizumab-awwb) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales decreased 17% year-over-year for the first quarter, driven by lower net selling price, partially offset by 15% volume growth. The published first quarter Average Selling Price (ASP) for MVASI in the U.S. declined 27% year-over-year and increased 5% quarter-over-quarter. Going forward, we expect continued net selling price erosion driven by increased competition.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">KANJINTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (trastuzumab-anns) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sales decreased 51% year-over-year for the first quarter, driven by lower net selling price and volume. The published first quarter ASP for KANJINTI in the U.S. declined 36% year-over-year and increased 3% quarter-over-quarter. Going forward, we expect continued net selling price erosion and declining volume driven by increased competition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Established Products</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Total sales of our established products, which include&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EPOGEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;(epoetin alfa)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> Aranesp</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;(darbepoetin alfa)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> Parsabiv</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;(etelcalcetide)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> Neulasta</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;(pegfilgrastim)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, decreased 17% year-over-year for the first quarter, driven by lower net selling price, unfavorable changes to estimated sales deductions, and lower volume. The published first quarter ASP for Neulasta in the U.S. declined 26% year-over-year and increased 3% quarter-over-quarter. In the aggregate, we expect the year-over-year net selling price and volume erosion for this portfolio of products to continue.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_10"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 5</font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Detail by Product and Geographic Region</font></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;AMGEVITA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;LUMYKRAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28%)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Change in excess of 100%</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="33" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">** Other products include Corlanor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, AVSOLA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, NEUPOGEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, RIABNI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, IMLYGIC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and Sensipar</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;Mimpara</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as well as sales by Bergamo and GENSENTA subsidiaries.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM &#61; not meaningful</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Expense, Operating Margin and Tax Rate Analysis</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a GAAP basis&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 12%. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> margin increased 2.2 percentage points, primarily driven by amortization of intangible assets from acquisitions, asset-related impairments, changes in product mix, and higher profit share. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research &#38; Development (R&#38;D) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses increased 10%, primarily due to higher investments in late-stage programs, research and the early pipeline, and marketed product support. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General &#38; Administrative (SG&#38;A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 2%.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Operating Margin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 10.7 percentage points to 32.9%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Tax Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">increased 5.6 percentage points, primarily driven by the 2022 Puerto Rico tax law change that replaced the excise tax with an income tax beginning in 2023 and an increase in the interest expense on tax reserves.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 6</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a non-GAAP basis&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 6%. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> margin increased 0.8 percentage points, primarily driven by changes in product mix and higher profit share. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses increased 12%, due to higher investments in late-stage programs, research and the early pipeline, and marketed product support. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SG&#38;A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 1%.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Operating Margin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 6.5 percentage points in the first quarter to 48.3%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Tax Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> increased 3.7 percentage points, primarily due to the 2022 Puerto Rico tax law change that replaced the excise tax with an income tax beginning in 2023 and an increase in the interest expense on tax reserves.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 pts.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General &#38; Administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3) pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,184</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,738</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,284</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,098</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6%</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Margin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">operating income as % of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6 pts. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7 pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pts&#58; percentage points</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* change in excess of 100%</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM &#61; not meaningful</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow and Balance Sheet</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company generated $0.7 billion of free cash flow in the first quarter of 2023 versus $2.0 billion in the first quarter of 2022, driven by the timing of payments for sales incentives, rebates and discounts, lower operating income, and higher capital expenditures from the build-out of our new North Carolina and Ohio facilities.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company&#8217;s first quarter 2023 dividend of $2.13 per share was declared on December&#160;12, 2022, and was paid on March&#160;8, 2023, to all stockholders of record as of February&#160;15, 2023, representing a 10% increase from 2022.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">During the first quarter, there were no repurchases of common stock. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Cash and investments totaled $31.6 billion and debt outstanding totaled $61.6 billion as of March 31, 2023.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 7</font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.029%"><tr><td style="width:1.0%"></td><td style="width:58.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.634%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.634%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.387%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions, except shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 &#8217;22</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Expenditures</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends Paid</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchases</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Diluted Shares (millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:58.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3&#47;31&#47;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12&#47;31&#47;22</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YTD &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Investments</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2023 Guidance (Excludes any contribution from the announced acquisition of Horizon Therapeutics plc)</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company expects the announced acquisition of Horizon Therapeutics plc (Horizon) to close in the first half of 2023. For the full year 2023, excluding any contribution from the announced acquisition of Horizon, the Company now expects&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.8pt">Total revenues</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $26.2&#160;billion to $27.3&#160;billion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">On a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP basis, EPS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $15.38 to $16.59, and a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 17.0% to 18.5%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">On a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">non-GAAP basis, EPS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $17.60 to $18.70, and a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 18.0% to 19.0%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Capital expenditures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be approximately $925&#160;million.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.8pt">Share repurchases</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> not to exceed $500&#160;million.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div id="ibc30363960d242a083f5a53e4ab02fe6_13"></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter Product and Pipeline Update</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provided the following updates on selected product and pipeline programs&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">General Medicine</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Olpasiran (AMG 890)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">A Phase 3 cardiovascular outcomes study of olpasiran, a small interfering RNA molecule that reduces Lp(a) synthesis in the liver, in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a) (Lp(a)), continues to enroll.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">In March, a new analysis from the OCEAN(a) Phase 2 Dose study was presented at the American College of Cardiology's 72nd Annual Scientific Session, together with World Heart Federation's World Congress of Cardiology. This analysis demonstrated that olpasiran treatment resulted in a placebo-adjusted percentage reduction in Lp(a) of &#62; 95% when dosed 75 mg or higher every 12 weeks irrespective of baseline Lp(a) level in individuals with ASCVD and Lp(a) &#62; 150 nmol&#47;L.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">In February, the Company announced the initiation of the African American Heart Study, in collaboration with the Association of Black Cardiologists and the Morehouse School of Medicine.  This study will measure the association between Lp(a) and ASCVD in 5,000 African American individuals to better understand the association between Lp(a) levels and incident ASCVD in persons of African American descent.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 8</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">AMG 133</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">A Phase 2 study of AMG 133, a multispecific molecule that inhibits the gastric inhibitory polypeptide receptor (GIPR) and activates the glucagon like peptide 1 (GLP 1) receptor, in overweight or obese adults, with or without type 2 diabetes mellitus, continues to enroll.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">AMG 786</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">A small-molecule obesity program continues to enroll patients in a Phase 1 study. This molecule has a different target than AMG 133 and is not an incretin-based therapy.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Repatha</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">In March, analyses from the Repatha FOURIER and FOURIER open-label extension studies were presented at the American College of Cardiology's 72nd Annual Scientific Session, together with World Heart Federation's World Congress of Cardiology, demonstrating that earlier initiation with Repatha was associated with a reduced number of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">EVOLVE-MI, a Phase 4 study of Repatha administered very early to reduce the risk of cardiovascular events in patients hospitalized with acute myocardial infarction, continues to enroll patients</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Prolia</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">In May, the Company will present results of the largest head-to-head, real-world study in postmenopausal osteoporosis, comparing fracture risk reduction of Prolia with bisphosphonates at the European Society for Clinical and Economic Aspects of Osteoporosis meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Aimovig</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">A randomized, double-blind, placebo-controlled Phase 4 trial investigating the efficacy and safety of Aimovig in patients with chronic migraine and medication overuse headache (MOH) met its primary endpoint (absence of MOH at month 6) in the 140 mg dose group. This group also experienced statistically significant improvements on the secondary endpoints of change from baseline in acute headache medication days and sustained MOH remission. Other secondary endpoints were consistent in favoring the Aimovig-treated groups&#59; however, they did not achieve statistical significance with the testing methodology applied. There were no new safety signals observed in the study, and the overall safety profile was consistent with what has been described</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Inflammation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">TEZSPIRE</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In February, the FDA approved TEZSPIRE for self-administration in a prefilled, single-use pen for patients aged 12 years and older with severe asthma.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In severe asthma, the PASSAGE Phase 4 real-world effectiveness study, the WAYFINDER Phase 3b study and the SUNRISE Phase 3 study continue to enroll patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 3 study of TEZSPIRE in chronic rhinosinusitis with nasal polyps continues to enroll patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 3 study of TEZSPIRE in eosinophilic esophagitis has begun enrolling patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 2b study of TEZSPIRE in chronic spontaneous urticaria is complete, with top-line data anticipated in mid-2023.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 2 study of TEZSPIRE in chronic obstructive pulmonary disease is fully enrolled. Data read out is anticipated in H1 2024. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Rocatinlimab (AMG 451 &#47; KHK4083) </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The ROCKET Phase 3 program, composed of seven studies evaluating rocatinlimab, an anti-OX40 monoclonal antibody, is enrolling adult and adolescent patients with moderate to severe atopic dermatitis.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 9</font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Rozibafusp alfa (AMG 570)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 2b study of rozibafusp alfa, an antibody-peptide conjugate that simultaneously blocks inducible T-cell costimulatory ligand (ICOSL) and B-cell activating factor (BAFF) activity, in systemic lupus erythematosus (SLE), was stopped for futility.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Efavaleukin alfa (AMG 592)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 2b study of efavaleukin alfa, an interleukin-2 (IL-2) mutein Fc fusion protein, in SLE was stopped for futility.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 2b study of efavaleukin alfa in ulcerative colitis continues to enroll patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Ordesekimab (AMG 714 &#47; PRV-015)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 2b study of AMG 714, a monoclonal antibody that binds interleukin-15, in nonresponsive celiac disease continues to enroll patients. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Oncology</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BLINCYTO</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Global regulatory authority submissions are planned in H2 2023 for E1910, a Phase 3 trial conducted by the National Cancer Institute, the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG ACRIN) Cancer Research Group that demonstrated superior overall survival with BLINCYTO treatment added to consolidation chemotherapy over standard of care consolidation chemotherapy in newly diagnosed adult patients with Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (ALL) who were measurable residual disease (MRD) negative following induction and intensification chemotherapy.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Golden Gate, a Phase 3 study of BLINCYTO alternating with low-intensity chemotherapy in older adults with newly diagnosed Philadelphia chromosome negative B-cell ALL, continues to enroll patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 1&#47;2 study of subcutaneous BLINCYTO in adults with relapsed or refractory Philadelphia chromosome negative B-cell ALL continues to enroll patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Tarlatamab (AMG 757)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">DeLLphi-304, a Phase 3 study comparing tarlatamab, a half-life extended BiTE molecule targeting delta-like ligand 3, with standard of care chemotherapy in second-line small-cell lung cancer (SCLC), will be initiated this month.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">DeLLphi-301, a potentially registrational Phase 2 study of tarlatamab being studied in heavily pretreated patients with SCLC, continues to enroll patients. Data readout is anticipated in H2 2023.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">DeLLphi-300, a Phase 1 study of tarlatamab in relapsed&#47;refractory SCLC, continues to enroll patients. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">DeLLphi-302, a Phase 1b study of tarlatamab in combination with AMG 404, an anti-programmed cell death-1 monoclonal antibody, in second-line or later SCLC, is ongoing.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">DeLLphi-303, a Phase 1b study of tarlatamab in combination with standard-of-care in first-line SCLC, continues to enroll patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">DeLLpro-300, a Phase 1b study of tarlatamab, in de novo or treatment-emergent neuroendocrine prostate cancer, continues to enroll patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 10</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Bemarituzumab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FORTITUDE-101, a Phase 3 study of bemarituzumab, a fibroblast growth factor receptor 2b (FGFR2b) targeting monoclonal antibody, plus chemotherapy in first-line gastric cancer, continues to enroll patients. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FORTITUDE-102, a Phase 1b&#47;3 study of bemarituzumab plus chemotherapy and nivolumab in first-line gastric cancer, continues to enroll patients in the Phase 3 portion of the study.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FORTITUDE-103, a Phase 1b study of bemarituzumab plus oral chemotherapy regimens with or without nivolumab in first-line gastric cancer, continues to enroll patients. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FORTITUDE-201, a Phase 1b study of bemarituzumab monotherapy and in combination with standard-of-care therapy, in squamous non-small cell lung cancer (NSCLC) with FGFR2b overexpression, continues to enroll patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FORTITUDE-301, a Phase 1b&#47;2 basket study of bemarituzumab monotherapy in solid tumors with FGFR2b overexpression, continues to enroll patients in the Phase 2 portion of the study.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">LUMAKRAS&#47;LUMYKRAS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:107%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company continues to investigate novel combinations and is advancing a comprehensive global clinical development program in NSCLC, colorectal cancer (CRC), and other solid tumors to further explore the potential of LUMAKRAS. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 3 study of LUMAKRAS in combination with Vectibix in third-line CRC is fully enrolled. Data readout is anticipated in H2 2023. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Combination study data of LUMAKRAS in combination with standard of care chemotherapy in NSCLC and LUMAKRAS in combination with Vectibix and standard of care chemotherapy in CRC will be presented at the American Society of Clinical Oncology annual meeting.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In March, the Company completed submission of the LUMAKRAS CodeBreak 200 Phase 3 confirmatory data, along with data from the Phase 2 dose comparison substudy, to the FDA and to the European Medicines Agency (EMA). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In February, results from a Phase 3 multicenter, randomized, open label, active-controlled, study of LUMAKRAS versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with mutated KRAS G12C (CodeBreak 200) were published in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Xaluritamig (formerly AMG 509)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 1 dose-escalation&#47;expansion study of xaluritamig, a bispecific molecule targeting six-transmembrane epithelial antigen of prostate 1 (STEAP1) in metastatic castrate-resistant prostate cancer (mCRPC), continues to enroll patients. Initial data readout is anticipated in H2 2023.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">AMG 340 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 1 dose-escalation study of AMG 340, a lower T-cell affinity BiTE molecule targeting prostate-specific membrane antigen (PSMA), in mCRPC, continues to enroll patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">AMG 193</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 1&#47;1b&#47;2 study of AMG 193, a small-molecule methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, continues to enroll patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 11</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Biosimilars</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In April 2023, the European Commission (EC) granted marketing authorization for BEKEMV</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (eculizumab, formerly ABP 959), a biosimilar to SOLIRIS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (eculizumab). BEKEMV is the first biosimilar to SOLIRIS approved by the EC.  BEKEMV is approved only for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening bone marrow disorder.  In February, the Company submitted the U.S. Biologics License Application to the FDA for this molecule.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 3 switching study to support an interchangeability designation in the U.S. for AMJEVITA, using an investigational high-concentration formulation of AMJEVITA (ABP 501, 100 mg&#47;mL) evaluating multiple switches between Humira</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (adalimumab) and AMJEVITA compared with continued use of Humira, met its primary endpoint of similarity for the primary pharmacokinetics (PK) endpoints, based on a prespecified PK similarity range. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A Phase 3 switching study to support an interchangeability designation in the U.S. for ABP 654, an investigational biosimilar to STELARA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ustekinumab), is ongoing. Data readout is anticipated in H1 2023.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The final analysis from a Phase 3 study evaluating the efficacy and safety of ABP 938, an investigational biosimilar to EYLEA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (aflibercept) compared with EYLEA in patients with neovascular age-related macular degeneration, is expected in H1 2023.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">TEZSPIRE is being developed in collaboration with AstraZeneca.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Rocatinlimab, formerly AMG 451 &#47; KHK4083 is being developed in collaboration with Kyowa Kirin.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Ordesekimab formerly AMG 714 and also known as PRV-015 is being developed in collaboration with Provention Bio.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">AMG 509 is being developed in collaboration with Xencor.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Humira is a registered trademark of AbbVie, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">STELARA is a registered trademark of Janssen Pharmaceutica NV.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">SOLIRIS is a registered trademark of Alexion Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div id="ibc30363960d242a083f5a53e4ab02fe6_16"></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 12</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this news release, management has presented its operating results for the first quarters of 2023 and 2022, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2023 EPS and tax guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, divestitures, restructuring and certain other items from the related GAAP financial measures. Beginning January 1, 2022, following industry guidance from the U.S. Securities and Exchange Commission, the Company no longer excludes adjustments for upfront license fees, development milestones and in-process research and development (IPR&#38;D) expenses of pre-approval programs related to licensing, collaboration and asset acquisition transactions from its non-GAAP financial measures. GAAP financial measures are included in the news release. Management has presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the first quarter of 2023 and 2022. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. Management has also presented Total Revenues and Product Sales Adjusted for Foreign Exchange Impact, which is a non-GAAP financial measure, for the first quarter of 2023. Total Revenues and Product Sales Adjusted for Foreign Exchange Impact is computed by converting our current period local currency product sales using the prior period foreign exchange rates and comparing that to our current period product sales.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity. The Company believes Total Revenues and Product Sales Adjusted for Foreign Exchange Impact provides supplementary information on the Company's product sales performance by excluding changes in foreign exchange rates between comparative periods.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Amgen</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the &#34;World's Best Employers&#34; by Forbes and one of &#34;America's 100 Most Sustainable Companies&#34; by Barron's.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 13</font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the proposed acquisition of Horizon Therapeutics plc, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 14</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">be guaranteed and movement from concept to product is uncertain&#59; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACT&#58; Amgen, Thousand Oaks</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jessica Akopyan, 805-440-5721 (media)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arvind Sood, 805-447-1060 (investors)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_19"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 15</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income - GAAP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:74.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.828%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,105&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,184&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(543)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,442&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in calculation of earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_22"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 16</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets - GAAP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,305&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,703&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,186&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,427&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,393&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,080&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,531&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,529&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,633&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,720&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,121&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,381&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,215&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,687&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,761&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,354&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,864&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,720&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,121&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_25"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 17</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in millions)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"></td><td style="width:74.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.850%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,720&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,561&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to cost of sales&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(610)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to cost of sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(704)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(610)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,016&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">951&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,058&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">959&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to research and development expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,044&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">934&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,228&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to selling, general and administrative expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(34)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,224&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,213&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,184&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,738&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(704)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(610)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(34)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(141)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(900)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(640)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,284&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,098&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 18</font></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"></td><td style="width:74.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.850%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,921&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,500&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">640&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,821&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,140&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost savings initiatives (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP interest expense, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(295)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to interest expense, net&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense on acquisition-related debt (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP interest expense, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(420)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(295)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP other income (expense), net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(530)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to other income (expense), net&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income and other expenses on acquisition-related debt (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity method investment basis difference amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (gains)&#47;losses from equity investments (e)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,853)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to other income (expense), net</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,859)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP other income (expense), net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(118)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP income before income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,442&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,675&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to income before income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">640&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to other income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,859)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to income before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(836)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,052&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP income before income taxes</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,606&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,727&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP provision for income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (f) </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(117)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP provision for income taxes</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">465&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (f) </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,841&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,476&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to net income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to income before income taxes, net of the income tax effect</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(719)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">863&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to net income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(700)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">867&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,141&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,343&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_28"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 19</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computations for GAAP and non-GAAP diluted earnings per share&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:52.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>March 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,841&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,141&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,343&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.28&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:3.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related primarily to noncash amortization of intangible assets from business acquisitions.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three months ended March 31, 2023, the adjustments related primarily to severance expenses associated with our restructuring plan initiated in early 2023.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three months ended March 31, 2023, the adjustments related to the change in fair values of contingent consideration liabilities. For the three months ended March 31, 2022, the adjustments related primarily to an in-process research and development asset adjustment.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three months ended March 31, 2023, the adjustments included (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit and term loan credit agreements, incurred prior to the closing of our proposed acquisition of Horizon Therapeutics plc.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three months ended March 31, 2023, the adjustments related primarily to our BeiGene, Ltd. equity fair value adjustment.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets, whereas the tax impact of other adjustments, including expenses related to restructuring and cost savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rate for the adjustments to our GAAP income before income taxes for the three months ended March 31, 2023, was 14.0% compared to 18.0% for the corresponding period of the prior year.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(g)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related to certain acquisition items, prior period and other items excluded from GAAP earnings.</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_31"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 20</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliations of Cash Flows </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.590%"><tr><td style="width:1.0%"></td><td style="width:69.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,509&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,514)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash and cash equivalents</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,931&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,560&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,528&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_34"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 21</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Total Revenues and Product Sales Adjusted for Foreign Exchange (FX) Impact </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in millions)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:13.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FX impact $ </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2023 excluding FX</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FX impact % </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change excluding FX</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Sales</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,105&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,208&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange impact was calculated by converting our current period local currency Product sales using the prior period foreign exchange rates and comparing that to our current period Product sales.</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibc30363960d242a083f5a53e4ab02fe6_40"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 22</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of GAAP EPS Guidance to Non-GAAP </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EPS Guidance for the Year Ending December 31, 2023</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Known adjustments to arrive at non-GAAP*&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net charges related to restructuring and cost savings initiatives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)&#47;losses from equity investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.70)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.60&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.70&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* The known adjustments are presented net of their related tax impact, which amount to approximately $0.48 - $0.50 per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The adjustments relate primarily to noncash amortization of intangible assets acquired in business acquisitions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, including any impact of the proposed Horizon acquisition, divestitures, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of GAAP Tax Rate Guidance to Non-GAAP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Rate Guidance for the Year Ending December 31, 2023</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:74.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate of known adjustments discussed above</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20230427.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fa651973-2c88-43d0-a2e8-806f3a520803,g:a19d5020-bb4e-4934-9fa2-38cf90db5df6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20230427" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20230427">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20230427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20230427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20230427_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.amgen.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CoverPageAbstract" abstract="true" name="CoverPageAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20230427_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fa651973-2c88-43d0-a2e8-806f3a520803,g:a19d5020-bb4e-4934-9fa2-38cf90db5df6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20230427.xsd#CoverPageDocument"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended" id="i096b9c27baad4ec9af7c0df0b12adbf1_CoverPageDocument">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_051adcfc-4b74-48e7-9f79-cf2547ee4f21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityCentralIndexKey_051adcfc-4b74-48e7-9f79-cf2547ee4f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c4220a0b-58b3-428b-9b7e-479fb2e8c32a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_AmendmentFlag_c4220a0b-58b3-428b-9b7e-479fb2e8c32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_23fd6241-e6c7-41d0-99ff-880677e5f654" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_SecurityExchangeName_23fd6241-e6c7-41d0-99ff-880677e5f654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_531606bf-03ea-4145-97ba-6f8be9c492a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_531606bf-03ea-4145-97ba-6f8be9c492a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c6e8e516-1012-417b-b941-e6fb581900f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_PreCommencementTenderOffer_c6e8e516-1012-417b-b941-e6fb581900f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0ec05bfe-0036-4c03-937f-c4f2287fd38a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_SolicitingMaterial_0ec05bfe-0036-4c03-937f-c4f2287fd38a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_bde19582-18f3-4ffd-a69f-d2a02c34976d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_WrittenCommunications_bde19582-18f3-4ffd-a69f-d2a02c34976d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2fc8b1b1-1a0f-4e8e-8b7f-ea888a56d403" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2fc8b1b1-1a0f-4e8e-8b7f-ea888a56d403" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2a8d3a7c-1cfd-4400-be89-6ca4a444bcd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_DocumentType_2a8d3a7c-1cfd-4400-be89-6ca4a444bcd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_49c19260-950b-44ef-9c30-b55e0f595977" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_DocumentPeriodEndDate_49c19260-950b-44ef-9c30-b55e0f595977" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a5e65241-c5e9-4ce2-b559-4430aaa9d647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityRegistrantName_a5e65241-c5e9-4ce2-b559-4430aaa9d647" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_42067489-c13c-4f54-a6b1-d701dc5decde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityFileNumber_42067489-c13c-4f54-a6b1-d701dc5decde" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_71f99cb4-389a-40f1-8a66-e966cf2442a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityTaxIdentificationNumber_71f99cb4-389a-40f1-8a66-e966cf2442a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd15489e-e18d-4171-bc2e-c2d86050f8e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressAddressLine1_fd15489e-e18d-4171-bc2e-c2d86050f8e3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_417d762f-51c9-4f5c-ba24-05ffe7878200" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressCityOrTown_417d762f-51c9-4f5c-ba24-05ffe7878200" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_732302b8-30f5-4899-9a59-112f81119072" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressStateOrProvince_732302b8-30f5-4899-9a59-112f81119072" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c5c678e3-dadf-43ae-adce-25963b037404" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressPostalZipCode_c5c678e3-dadf-43ae-adce-25963b037404" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b0c4c3e1-2ef5-4abf-977c-0fcc2b1575fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_CityAreaCode_b0c4c3e1-2ef5-4abf-977c-0fcc2b1575fd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_852791dd-2372-4e76-a656-8f56d686aaca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_LocalPhoneNumber_852791dd-2372-4e76-a656-8f56d686aaca" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fe93ea64-244d-4f8b-9979-0532f9e263cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityEmergingGrowthCompany_fe93ea64-244d-4f8b-9979-0532f9e263cf" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7cb51b62-981c-446d-b055-2a994d21f97b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_TradingSymbol_7cb51b62-981c-446d-b055-2a994d21f97b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c10af019-f78f-4bed-9b31-5531f84fd311" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_Security12bTitle_c10af019-f78f-4bed-9b31-5531f84fd311" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:to="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_9799dcc1-9f30-4f5b-ae96-681713f6c5df_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:to="loc_dei_ExchangeDomain_9799dcc1-9f30-4f5b-ae96-681713f6c5df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_e7ee36e9-b34b-4d90-b5eb-144c07150e67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:to="loc_dei_ExchangeDomain_e7ee36e9-b34b-4d90-b5eb-144c07150e67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_4765cee3-e81d-49da-a47e-0588e056e462" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_e7ee36e9-b34b-4d90-b5eb-144c07150e67" xlink:to="loc_exch_XNGS_4765cee3-e81d-49da-a47e-0588e056e462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:to="loc_us-gaap_ClassOfStockDomain_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:to="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_728d28dc-b1db-4185-a9be-24fb1c36398f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:to="loc_us-gaap_CommonStockMember_728d28dc-b1db-4185-a9be-24fb1c36398f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_c0ac919e-0a8e-44df-a541-ef1e5b1ebec7" xlink:href="amgn-20230427.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_c0ac919e-0a8e-44df-a541-ef1e5b1ebec7" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20230427_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fa651973-2c88-43d0-a2e8-806f3a520803,g:a19d5020-bb4e-4934-9fa2-38cf90db5df6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_46489a80-0f5c-4c04-a692-8887a0ab47d9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c7b350f8-4d30-4f02-beb9-a3f244612a33_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d89dbd28-898a-4472-981e-b89d4a15fefe_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_79c6dc14-ebfd-49c8-afe5-23f1ccdc44b8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_e287bf8f-69af-43a1-9a10-6dde3e8c0de6_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c918a02c-dbe6-4a04-a42e-bb89668895d5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_890642e3-8979-413c-9f9d-a98fde07c306_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_282408ee-5ad1-421d-9c7c-84c7acac0830_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0bb9e8df-1386-4f2c-bf21-50ee92ab66ab_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_4052b168-98c5-4c4a-ac60-04d85817a49f_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1fc8b8b2-ac1a-43a4-8932-b83522fd8af1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_d5a63c3f-4e05-4ac9-9f1e-b6dc2154b9b3_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e28ae10c-4d01-4a65-bbf6-7af853014056_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_0f390807-ab53-4714-84a9-dadb5f74a919_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_946cd911-751d-495a-bb82-9dc31190ca5b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2350abd7-9541-4b11-ae8e-5b455f9ba3c6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c325d802-da12-4cc4-a8f3-6f7aabc0a600_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_35ea9861-19f7-41a8-8acf-3bfc3d8a7c5e_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20230427.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CoverPageAbstract_ba93d3e3-19e9-4e44-a4dd-ecbe57d83711_terseLabel_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_label_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_documentation_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract" xlink:href="amgn-20230427.xsd#amgn_CoverPageAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CoverPageAbstract" xlink:to="lab_amgn_CoverPageAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_23a85a2d-2a9a-47a9-b26e-15642d6f1c0d_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c3bcaaa2-3d46-4dc8-b6a1-0013cda4b179_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_78f524e5-dbb5-41da-8283-b822872e8581_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_bff4f6ea-c15f-4d18-87cf-47e7e6cc3369_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0333f926-affd-4ae5-b52b-46652b70a413_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1d4c31d1-4fca-4ee0-b9ef-36f0c7e61048_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_94a99c31-6ba9-4775-b40a-e28187d0633f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1e81abe0-8459-4a2e-86ab-fcd59ede7604_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_04dacd74-7a23-48a9-8961-0de11e90e372_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0b2987d2-cbef-41cf-9202-1e8e511a03ea_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_15e646b0-d0c0-41b0-9e43-c536200edb0d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d59dbedb-ddef-4523-bf5b-8a462ab98731_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_aa2532ed-c38d-4567-8486-e49aa9348852_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20230427_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fa651973-2c88-43d0-a2e8-806f3a520803,g:a19d5020-bb4e-4934-9fa2-38cf90db5df6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20230427.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract_c357b422-ead4-4bda-8afb-a4c259fc8e32" xlink:href="amgn-20230427.xsd#amgn_CoverPageAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_CoverPageAbstract_c357b422-ead4-4bda-8afb-a4c259fc8e32" xlink:to="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:to="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_e7ee36e9-b34b-4d90-b5eb-144c07150e67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_9799dcc1-9f30-4f5b-ae96-681713f6c5df" xlink:to="loc_dei_ExchangeDomain_e7ee36e9-b34b-4d90-b5eb-144c07150e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_4765cee3-e81d-49da-a47e-0588e056e462" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_e7ee36e9-b34b-4d90-b5eb-144c07150e67" xlink:to="loc_exch_XNGS_4765cee3-e81d-49da-a47e-0588e056e462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5b2abf34-aa68-4f7c-9dd8-4201f9c72a40" xlink:to="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_728d28dc-b1db-4185-a9be-24fb1c36398f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:to="loc_us-gaap_CommonStockMember_728d28dc-b1db-4185-a9be-24fb1c36398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_c0ac919e-0a8e-44df-a541-ef1e5b1ebec7" xlink:href="amgn-20230427.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00155a4b-fa64-47da-90ca-2d86a9c4dc3c" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_c0ac919e-0a8e-44df-a541-ef1e5b1ebec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4c45da6c-f2d4-42a2-939f-04179e88cfd8" xlink:to="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_051adcfc-4b74-48e7-9f79-cf2547ee4f21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityCentralIndexKey_051adcfc-4b74-48e7-9f79-cf2547ee4f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c4220a0b-58b3-428b-9b7e-479fb2e8c32a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_AmendmentFlag_c4220a0b-58b3-428b-9b7e-479fb2e8c32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_23fd6241-e6c7-41d0-99ff-880677e5f654" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_SecurityExchangeName_23fd6241-e6c7-41d0-99ff-880677e5f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_531606bf-03ea-4145-97ba-6f8be9c492a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_531606bf-03ea-4145-97ba-6f8be9c492a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c6e8e516-1012-417b-b941-e6fb581900f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_PreCommencementTenderOffer_c6e8e516-1012-417b-b941-e6fb581900f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0ec05bfe-0036-4c03-937f-c4f2287fd38a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_SolicitingMaterial_0ec05bfe-0036-4c03-937f-c4f2287fd38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_bde19582-18f3-4ffd-a69f-d2a02c34976d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_WrittenCommunications_bde19582-18f3-4ffd-a69f-d2a02c34976d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2fc8b1b1-1a0f-4e8e-8b7f-ea888a56d403" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2fc8b1b1-1a0f-4e8e-8b7f-ea888a56d403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2a8d3a7c-1cfd-4400-be89-6ca4a444bcd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_DocumentType_2a8d3a7c-1cfd-4400-be89-6ca4a444bcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_49c19260-950b-44ef-9c30-b55e0f595977" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_DocumentPeriodEndDate_49c19260-950b-44ef-9c30-b55e0f595977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a5e65241-c5e9-4ce2-b559-4430aaa9d647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityRegistrantName_a5e65241-c5e9-4ce2-b559-4430aaa9d647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_42067489-c13c-4f54-a6b1-d701dc5decde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityFileNumber_42067489-c13c-4f54-a6b1-d701dc5decde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_71f99cb4-389a-40f1-8a66-e966cf2442a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityTaxIdentificationNumber_71f99cb4-389a-40f1-8a66-e966cf2442a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd15489e-e18d-4171-bc2e-c2d86050f8e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressAddressLine1_fd15489e-e18d-4171-bc2e-c2d86050f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_417d762f-51c9-4f5c-ba24-05ffe7878200" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressCityOrTown_417d762f-51c9-4f5c-ba24-05ffe7878200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_732302b8-30f5-4899-9a59-112f81119072" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressStateOrProvince_732302b8-30f5-4899-9a59-112f81119072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c5c678e3-dadf-43ae-adce-25963b037404" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityAddressPostalZipCode_c5c678e3-dadf-43ae-adce-25963b037404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b0c4c3e1-2ef5-4abf-977c-0fcc2b1575fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_CityAreaCode_b0c4c3e1-2ef5-4abf-977c-0fcc2b1575fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_852791dd-2372-4e76-a656-8f56d686aaca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_LocalPhoneNumber_852791dd-2372-4e76-a656-8f56d686aaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fe93ea64-244d-4f8b-9979-0532f9e263cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_EntityEmergingGrowthCompany_fe93ea64-244d-4f8b-9979-0532f9e263cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7cb51b62-981c-446d-b055-2a994d21f97b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_TradingSymbol_7cb51b62-981c-446d-b055-2a994d21f97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c10af019-f78f-4bed-9b31-5531f84fd311" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_7eef016f-846d-4059-9f3d-8cb535289281" xlink:to="loc_dei_Security12bTitle_c10af019-f78f-4bed-9b31-5531f84fd311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>amgenlogoa14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgenlogoa14.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !& .P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MFLVVL?7/$%AX<TNXU'5+R&QL;=-\EQ<'8BCZFA:M)=29245=[&U3/EKY%^(G
M[?VCZ3/-9^#]&DUQT./MUX3! ?\ =3[Y_2O)[W]O?XC27#F*PT.SC[)]GD?'
MXEZ^EPW#N8XF/,J=EYNQ\EB.*LKP\W#GYFNRN?HFM.KY&^(G[4WBKP-\,_AW
MXD@L=+O+SQ!;23W<<T;A 5V[=F'XZU+\+_V[M#\07,5CXOT[_A'9Y#M%["YF
MM?Q[I7*\EQWLG6C#FBFT[:[.ST.M<0Y?[94)3Y9-)ZZ+5)K7T9]:45G6-]!J
M=I'<6TL<UO(F^.2,[D8=B#5]?NBO$/HTU)70ZBF'/:O'_C%^TIX2^#?^CZC,
M;[66&4TRSPTV.Q<]$'UK:C0JXBHJ5&+E)]$<^(Q-'"4W5KRY8KJSV.BOA_PW
M^W+XF\8?$+0M'M_#VF:;IFH7\-J3(\DTVQW /((&?PK[$\1>)=.\(Z+<ZIJ]
MY#I^GVR;Y+FX.U$%=F,R[$X"4(5XV<E=(X,#FV$S",YT)>[!V;>B-9V^:G;M
MW2OAOXK_ +>U[<74MEX%TV*"%=RC5=2CRYQW2/M^->#ZQ^TA\3=;N&EN?&>I
M*>NRUD\A!] @%>WA>%L=B(>TE:"\[W_(^=QG&&7X:?)33GZ6L?JYNJ2ORDT#
M]ICXF^'9Q);>,+^<=X[QQ.A_!Z^EOA#^W7;ZM/#IWCRTATMI"$35K//D9_Z:
M(>4^HXJ<7PSC\)!SBE.*[;_=8TP/%V7XR?LYWIM_S;?>C[%HJA9WL6I6T=Q;
M21S02+O21#N##L0:^2_BC^V[K'P]^(6O^&XO"UG=P:;<FW2XENG1I,*#G 'O
M7@X/!8C'S=/#QNT?1XW,L-E]-5<3*T7HMW^1]AT5\)_\/$M9_P"A.L/_  .?
M_"C_ (>):S_T)UA_X'/_ (5['^KF:?\ /K_R:/\ F>-_K5E'_/W\'_D?=E%?
M,9_:TO+;X$Z=\0KCPY&[W&J&PDL8;D\(-WSAR.O%>B_"/]H;PG\9+5AH]YY&
MHQIF73+KY)X_H/XQ[BO*JY?BJ$'.=-V3LWO9H]:CFN#KU(TH5%S-)I=T]CU>
MBH0QKQ[]I3XW7GP-\*Z7JMCI<.JM=WGV8QS2% !L9MV1]*Y:%&IBJD:5%7D]
MCMQ.)IX2E*O6=HQW/9Z:U?"[?\%%-93[W@VP7_M^D_\ B*^D="^+4^J?!./Q
M]/8QQ/)IKWHLPYVAQD!<GL37H8K*L9@U%UX6N[+5;GEX/.\#CW*.'G=Q5WH]
MCU/<OK3_ #*^/;OQ[XR_X3:31AXBNW\4?VC':)'"Y^S%C&DC[;?R=AB3?SF3
M?CFOI7X>^+E\7>"M'UF=8K6:]@622(OP&Z-M_P!G(.*Y<3A)86"G)Z,WP>94
M\9.5.*LUW\M_NZG8444QL>M<9ZK.7\>>-M*^'?AF]\0:U<+:Z?9KO=OXF/\
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M9'&3SBNC+L^Q$KQQ]"2\XQE^*,,RX=PU.TLNQ$9=TY1O^96_8Q^/\^A:U;>
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MXJ_4+]G[1[?7OV<_"=A>1+<6MQI7D21MT*$D$?E7Y=-_%7ZK?LP_\D#\#_\
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M=K:]D6/V#?AY:>(O%7B+6]2LX;VSL;5+6-+B,2)YLAWDX(ZX2OMO_A ?#O\
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M[U\:?]##H?\ WQ+_ /$4?\.]?&G_ $,.A_\ ?$O_ ,17TTLYR>;O*I%OT?\
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I%%% !3*** Z!'3Z**!(****!A1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139684852674960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 27,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | 2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.000% Senior Notes due 2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>amgn-20230427_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20230427"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20230427.xsd" xlink:type="simple"/>
    <context id="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl80L2ZyYWc6MDczMWQ3Y2EyMjcyNDhiMTg2ZjA1ZjBjOWEwMDUxZjAvdGFibGU6ZmQzZTEwYWZmOGJiNGZmMWIwZTYyMzc2MmM5YjA1YTYvdGFibGVyYW5nZTpmZDNlMTBhZmY4YmI0ZmYxYjBlNjIzNzYyYzliMDVhNl8zLTEtMS0xLTIyNTY3OQ_fc06d8f7-f7cb-4075-b3d0-2e825e193aca">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl80L2ZyYWc6MDczMWQ3Y2EyMjcyNDhiMTg2ZjA1ZjBjOWEwMDUxZjAvdGFibGU6ZmQzZTEwYWZmOGJiNGZmMWIwZTYyMzc2MmM5YjA1YTYvdGFibGVyYW5nZTpmZDNlMTBhZmY4YmI0ZmYxYjBlNjIzNzYyYzliMDVhNl80LTEtMS0xLTIyNTY3OQ_561d5a39-d922-49a2-8283-e9ba1f46fd47">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTE5_6116eeb3-217a-4870-b5d4-b63487791514">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8yMjg_5fd16a89-0716-46f7-b3e8-9ce4551bd230">2023-04-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTIx_94002c5d-1c52-4d85-8adc-6ac54fa8350c">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8wLTAtMS0xLTIyNTY3OQ_6a1bf2e1-3050-4000-95e2-6ddaef1e5adb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8wLTItMS0xLTIyNTY3OQ_fcb9b1e9-680e-4559-980f-479c50b3d7e1">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8wLTQtMS0xLTIyNTY3OQ_f056487b-5b99-415c-b573-da56038b402c">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV8zLTAtMS0xLTIyNTY3OQ_35991dbe-aa24-422e-ae3a-9fc7a9b27ca6">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV80LTAtMS0xLTIyNTY3OQ_8f71aa4e-11f9-417e-ba99-b83772a0ba1c">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV81LTAtMS0xLTIyNTY3OQ_4da6cfeb-5709-4c14-a4e1-7074e3b276e2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6ODA1ZTE0Y2I1NjZhNDVhY2I3YmZkM2RlNTg2NThiNDUvdGFibGVyYW5nZTo4MDVlMTRjYjU2NmE0NWFjYjdiZmQzZGU1ODY1OGI0NV81LTQtMS0xLTIyNTY3OQ_f307a9d5-1cfc-4d1b-aa86-5a82161beda6">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTIy_263caf4d-9330-400c-806c-c7cc96a2ae22">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTE3_04dc098c-9917-4b61-9c6d-f494ca6dd56c">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6MzFkN2VjY2E4ZGE3NDQ4MGExOTBjMDJiMDc4YTY2MjMvdGFibGVyYW5nZTozMWQ3ZWNjYThkYTc0NDgwYTE5MGMwMmIwNzhhNjYyM18wLTAtMS0xLTIyNTY3OQ_2f8ee7fb-28c0-4ddd-ad5b-d762471249a8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6OWYxODRjZTdhMDg4NDliY2E2YjY0ZWNkM2Q2NGI2ZTkvdGFibGVyYW5nZTo5ZjE4NGNlN2EwODg0OWJjYTZiNjRlY2QzZDY0YjZlOV8wLTAtMS0xLTIyNTY3OQ_a045af4b-08c4-4f48-8b92-fd42fd178a29">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6NGUwMGM5YzUyOGUzNDVlMTlkM2EyYjA0ZGMyOTMzNDEvdGFibGVyYW5nZTo0ZTAwYzljNTI4ZTM0NWUxOWQzYTJiMDRkYzI5MzM0MV8wLTAtMS0xLTIyNTY3OQ_35494919-ea96-4f74-8e7c-12d3e9c19bce">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6NDUwYTFlY2JmZDRmNDdkY2JjZDZhNDAzODE0ZjVhZjUvdGFibGVyYW5nZTo0NTBhMWVjYmZkNGY0N2RjYmNkNmE0MDM4MTRmNWFmNV8wLTAtMS0xLTIyNTY3OQ_92c08aaf-2905-40b8-ae41-1d5b622d0d7e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8xLTAtMS0xLTIyNTY3OQ_3b40c6c5-5804-49a8-968b-92d46251f651">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8xLTEtMS0xLTIyNTY3OQ_a86404f6-6d36-4ebb-87ae-f5ecad030ef6">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4e7a815ceed7403bb041add5a7dab8b5_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8xLTItMS0xLTIyNTY3OQ_919bd774-a60b-4278-9f29-f1db134a7b03">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8yLTAtMS0xLTIyNTY3OQ_ff742b5e-d35b-4b99-82e2-3a1b2136d717">2.000% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8yLTEtMS0xLTIyNTY3OQ_8400ab10-9988-4ed5-8b32-00c4baf5199a">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifd60e8505ae444bb8529fd7511d9533b_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGFibGU6YTU5ZWMxZTJkZTE2NGExNmIxNDU4ZTZiZTkyNGQ2ZTYvdGFibGVyYW5nZTphNTllYzFlMmRlMTY0YTE2YjE0NThlNmJlOTI0ZDZlNl8yLTItMS0xLTIyNTY3OQ_ebf8cafa-4104-4c70-b664-0b346e6e19e8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xL2ZyYWc6Zjc0YTIwNDNhZGY4NDNhNDkxYWI2MzAzOTllYjNkOTEvdGV4dHJlZ2lvbjpmNzRhMjA0M2FkZjg0M2E0OTFhYjYzMDM5OWViM2Q5MV8xMTE4_1a09fb3a-8b47-4494-9633-75196a3b221c">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMmU2OTYxZTNlOTRmMGE4ZGU3YWU4MjkxNjFhODc2L3NlYzoxZDJlNjk2MWUzZTk0ZjBhOGRlN2FlODI5MTYxYTg3Nl8xMC9mcmFnOjVlYTY1YmI4NDhkNDQyMjE5ZjhlZTA2M2I4MGY5NzA2L3RleHRyZWdpb246NWVhNjViYjg0OGQ0NDIyMTlmOGVlMDYzYjgwZjk3MDZfNTQ5NzU1ODI2MTk4_5fd16a89-0716-46f7-b3e8-9ce4551bd230">2023-04-27</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M=:BM%Y_2S&?)&V924I&(+T'?/NJ!R\CME[[MCA9I_G7M7F@MXGQSS5G I;D
MSB\%W+/8,1_LRN^MPW\!4$L#!!0    ( 'R!FU:?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( 'R!FU8'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ?(&;5DDOZ63O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ ?(&;5IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !\@9M64AATH_H$  ![%0
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ ?(&;5I^@&_"Q @  X@P   T              ( !/@T  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !\@9M6EXJ[',     3 @  "P
M        @ $:$   7W)E;',O+G)E;'-02P$"% ,4    " !\@9M6VU\'[3D!
M   P @  #P              @ $#$0  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ ?(&;5B0>FZ*M    ^ $  !H              ( !:1(  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ?(&;5F60>9(9 0
MSP,  !,              ( !3A,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  F!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="amgn-20230427.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="amgn-20230427.htm">amgn-20230427.htm</File>
    <File>amgn-20230427.xsd</File>
    <File>amgn-20230427_def.xml</File>
    <File>amgn-20230427_lab.xml</File>
    <File>amgn-20230427_pre.xml</File>
    <File>amgn-2023331earningsrelease.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amgn-20230427.htm": {
   "axisCustom": 0,
   "axisStandard": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20230427_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amgn-20230427.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20230427_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20230427_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20230427.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 32,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 1,
   "memberStandard": 2,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20230427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20230427.htm",
      "contextRef": "i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.amgen.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20230427.htm",
      "contextRef": "i354a8adb98bb4a9aafbd9aded40cfa7a_D20230427-20230427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20230427",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CoverPageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover Page [Abstract]",
        "label": "Cover Page [Abstract]",
        "terseLabel": "Cover Page [Abstract]"
       }
      }
     },
     "localname": "CoverPageAbstract",
     "nsuri": "http://www.amgen.com/20230427",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "exch_XNGS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "terseLabel": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]"
       }
      }
     },
     "localname": "XNGS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000318154-23-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-23-000026-xbrl.zip
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M.6,);$J3E$(5!\MUB/;GC>9]2.-QPK]QO*SD["9XXRGL5E3$.*(4WP**W_V
M)1+O$%NKP([K_UF6C-7"A\5/R[6/@+XQ+;X!K"=9%:R@0^R4K!@RXN]JVJR;
M])ZL14KQO6CD8(E0:^EF@($# _ 8HV5#T5U7,51"@6_*E+BV:[X W?+ALQZ*
MO_A*H;')* R\(&NPH0M-T !2A8$Y5PH?@S0+HEY: P4++,J.)D&Z<XCJMO)W
M\_3\_<':NA[11&XC5<XS(#-VZS@D:=KRS[/8NQ*M%%F.X^$PCGB"J.?>5@]6
M!KH1_.)32V&VJ9B$&8;ANK:I.3XMFZI*'5/7W2V_/))?$ 8K1UI)4<Y9%,1)
M,\Y86ATSH)JU\8QSL(S7!PLVX@%8DL*<Y/ST+8_KJ[JS6"8W08=!)/<9>H45
M0RN5S5'V[B:@6;^B*LK_[BQG)4D/<KMQEL7#B@4YL8M@K2,'532M!(6A1#HB
MH.K<Y !:$Y]%HW>;7JI/Q>*B1A(&,*,>U,J2O,*BC!>'<5+YI\+_O?.!2K)/
MAD$XK?R[#4R32DUV(YW%0Q+]>S\%;PC<IB3P1<8TN&45U896^-<;,>HRU(,>
M5$$%5<-Q7S3K[5I5.F\?M6OGR^/8D!&<UXXOSNKM>NU<.FI6I=K?QW\>-4]K
MTG&KT:B?G]=;S5<V+.U1P[HD:1^ )HNC?:E:.BY)FF(:SO<,Y;D[;JSTVUC;
M[W_]4[64=T4_GY=RRA-Z\$HF_7&\?-(Z:T@_T44J FG"Q7])#VE2>$C=@:=T
MVO6;9K79[YYV#/S;K%Y-.I=UK7%[=-MJAV%GT+QJM6O@[7PQZ)]_A5TMO'8'
MHV'S]JS?&!PI#>WDJCOHP=^:TFJ?]#N#SFVCVC!;EU^"AO;9;'RQ)XUVS?QJ
MJ:K%F*O+FEHFLF&7%=DUJ2&[E@Y?RHYJJL;.H2W_9]6[D;:"MZ&"]SBT!15R
M5FNVI;/:I]99>R.'\&F<I&,295(62^?,P\BHF!!5EUIGDFKNTCTI]C=R;.T^
MPS&-DR +H-;"^):.O R&)*F.;KRR<3U.8M RQ@&<L5&<9-)N\9T1L(U9FDGL
M&I<]$I[,Z-Y&#O(7Z+-/W*FH"5=C1Q)+ U#])*M0^$4&]SKK8S&9DJD\!?+*
M+/J]%."T,>A]-7VJ6L1V9*6L6K)A^679U9DM.QXS3%-U*9!XY_!HE 2AP ZM
MO,\7T>Y&^S9#'<JO2V*TU;ZOA[N?OA1RQGI!BJMH61-2?B]! $NP/OGJ -=H
MGDEEU3,UV:"V*0-5/=DBGFGXQ-9-Q0-)P 4^J1YYI1\R"%\-%._6)@14)K(#
MJIEDQ@822:5TQ#R,CU$IB*0@2R50LJ!UDN_2.B\T,"'MWV6 6NOF97VD)R-N
MR(I:W#BA+)%A9"$9I:Q2?'A7+'**A6J9%WJWW";RPC5+LL C8=XN;U DSP-2
M)44$I;($_M.BY3RYQ),.,GHW3==*MFK?FZR4U">FV9K^I)(/=E8I.6IYDSKK
M/*K: SYK8N: .9 9/^SH.T6!$:$TB'H5;321U+4\N,(A@CE^NF#=447*+U%%
M *YQ N8MW\K!@]_'\3C*DNEQ3)=-.=P9@I'GC(V2^!KKV5 ;3BSSMJI':K==
M4SI:76T.NI#_2Q\^ZYUA]ZJA07OMGM9L]X-F]6)EF3<V&M4O8:-]-N@,+K3F
ML*8T+T_@,PWXTO'IA=JJ=M36:5UI?K%O/K:/5I=Y+:*ZOL9465=,109$563'
M9)IL44J8KS(3)A6<$Q:2&Y*L6>G-\347A._C\9#Y=S#P%W'X'=6AK(E:/&E0
MOZ/@G@0A@]I=,&:V0OAM(:S?W4GC.J[*'-FR%2:#^^7(CJWXLE%V/%-Q=5IF
M*JYC@I26RXJVE<*M%*Z1PC:9U/.%;8^KT*U(/EHD/]\12<6T#+OLRJ;K.+*A
MFI[LFF5=IL2T%-UV#7 9=PX=4X:I4\IEZT&9W PS<'5=:KUT[G+#3(H3*<[Z
M+)$&XR1(:<"#S'P%')S)8-&0V]O"TR9,*^X\"M*TF$54Z9( D.T$;L0$UL_.
MI=IP%,93EO I7%8&4C,N[:U#I:*?>6VZ"',\2! %R;'S*-J]KJQK@=AY;1/^
M6@R*(TH3EJ;YGX_0 75K3'S+F+A=XV3KIN.HU&4R(9HA&YH&GYA.9,?WRL1Q
MM;)'K)W#5L0D$64^YLPF59/@>NMR;^7YF>7Y&#ZVDG9\LPV9?5.:E372;/ME
ME1"#R:KJHVM09K)+P$EP;?#.-:*X1/5PGT(\!FZ@4HM<I3\@Q%M5]PM%@_LV
MK>13$E\'_,3<-N;\@P*DKA$@@Q++\QGXUF4%!,A3#1G$297+2ME@.JA#BVD[
MA\? =T#^*""_1GJVDK H"9]B8/6P&XS$VLN6S;_)YG=#2+H"UATU9=7S/=F@
MJ@OVGVW))K$UU5)=1M'J<U1=4V2U[#C?'T)Z=7#^2%<UYS'<=S!* &B#$0DE
M-F'>. .+%WX&IY6EV[C#1DPF8(2$(+$FN'# -SYLV,:8^8:H?_T3!+7\+I4R
M%K)1/P;_+.(1L7V,<(9CG"2))(S )%+VRG<!K=]>MOL3]0GZ&4= G8W5(#^T
MKVSZ5;-TC_@&E1U=YTOK'MXKXLE>V?,<BVB$:6#FV(JY"OQ[/_/<Q\<8<.,3
M,O,&+P_]T-D/_:MB4$]Q;$]V'+4L&ZZERHYG4=DW',,C%J6F!1Z<891EP#CE
MY^SW6W=<\/%5#<9I%OC3%X+(XS[SKJ2LSR0R F<(=#@N";GQ1')9&-](@<\3
M3\!YDFSY/Y(?A B500JXF;$(>!5/)J3!<!QF)&+@*(=3*259D/I37C(O$+LP
M6!&]CD65"]L4QU!/(I%H6J3Y<0B-8SETT )<RD@KC]\!^,LW]SE.R3;UI^SM
MTXJ"S[JOS3%*CO&X37A/7]#DES']J/UR! P72A=1@'I7:IP_]D3)>@OF)X+M
M91)DP/"XMC:.\H68]&Y4P8WCT"7 O1G(T$8"LG"V&K<G5TWMRZ"C87]J>K/Z
MV8"^35KM/P:-ZE]!H^H9G79':PP:J\X6OQJE>]D<=-K]JT[;4YK5WDVG73,;
MIXV;QA#Z<=OO0^JTH:[=QZ;Y-F-EWY4UVP-E2RF5"35=F98MS2BKFN$0&TUP
MIVP8[]YX3#WG.AC& MM)HX5#86=CP#E#,W,0S9;/5.%1JEVU+!V?G$G TR7(
M^'3C?HNL6V3]"<AZ'O-++8 6#; ]L-=O%U9;EYU)JWHVZ+9IOU'M09DP (C5
MP+Y5 #*OP+;5FJ=U#?JP"JMF=U SFJ=-Z%/MIE7M*:W+OP!BNT%S<!9VM,^W
MW6I'Z0RZ86O]]F"B&";X,*ZLV)XA&[YAR[;K:+)/#<VG:MDFFO.[P.J<Y:1A
MSG-W054UB*QJ"[BZ=$!UAJH&R#S/N076+;"^*F#]E# T5_'F-'X]!+IK2<OW
M,5+P5@&V>7IQ W:FV;F]F+9.+VZ;// ? K#6IIW!D=(];4Q;[0;\7EL%6*7;
M/KKIW(:#9KMN=-L-I7EY,6E=?K[MM-'>/;OJW$(_;QM*8SW PFPYAJ,Z,B..
M!0!;-F2;E3U !JHSQU,=UV._"\ "Z\G> N]]RX!5#2IKN^[>X]!6Y-WB[19O
M7S/>UM-TS)+? W6K%^#AGX 9^M>P6ST;-JOT"CX/NE5<IH4RU1JT_:7?'=Q9
MFE6:[3_ZC<LO US&;9YVE*9V!I^;5[A,VZ@VC :,LWEY,KSGU)NC>8H-,R5K
MCF+*AN+:,F&&*JO4="U-HPHM;U'W/M35F6SL>H]#W3SO#ZX-OE"8>R$D(N+.
M+&%TB2#YY3J2RM50'H<&(GQ'V'GM L&F:!E=*Y6UIYW-?E!YZ27+>'[M!0RI
MZ]8;.KC]N!7Z-E[(+JX2\OJ2AW>)OK5-".V$\,7X\^G0C</=']TZ\OH&V,RO
MZ>!3R JX!>2YZ0?PRQR>-O#<V3/L?'O*/=2+P40!]%-5<[FP;+!1U6E?F-W+
M!O3KKZMNNZ8U3VN3YK ^ 6,+W--N &U/FZ>?M>[=&^/[3:SO]B1L#,_ _>U
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MC <(L$2N0(CH&=]8(A@*F+WHS9*ML4" I341C(>308SGAI!6J^').X$95$L
MK2+<MM@5!"B.B?>T-+-P%N#R\1[M/OJC+**IN/AC?LI$.'T"4\ F@,IX9W,Z
M0P.X5LF7<5;HG*_\W)V,8B)Y%0B(2Z7>U.+WRC8>W." >PZ%A5:HV@707%BH
MGCFGR&3WQ[Z@F^ A<=;GJX,"K!_0)P_0]W53D[_PL!S=X);>PF\Y;>_;1I7V
M<3D>UP5=Y&6@&I4XQ$+'@Y!1_EE]=R<V,-N0;S_RK!-?!2!#OD=P?_:<^4V
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M?)U).++V+/UW$EZMKYUTMVEI,-G5.K"NNOH&W==MXS2;58LV%\E<OROT+)_
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MMW-1F%;I+4#F6_]7MPQ6*$IYO%NP $-=#$+O:/2$)ZN]BS)%$2=FY:$7FYE
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MT#Z_>K9ZH_O6_;^+5\_^#U!+ P04    " !\@9M6$)C3 'ET   "2@< 'P
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M!E<7R22SH/!(-!WX?6"2![AZ"0\$8&[1Q^0%Y,_3RV_G'XI&BP'/Q5UN17&
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MA8N%GZ((?S< !P*C/<22X\@E?$_B6C)=!]P79,4>R%DT_Y4F.XL#T'^@R6Y
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MIBB1N +_:ERN%9>!/R5RY^*2N,W&!HU['SEM%"DIBKX XPSVX8DX\,%Z\ZU
M#87$OA"A;*OG(O55GL0>/*8+670ARY,KI4(6HYSM\4?O11^<OBC^.P8YHH7W
MNH3W1Z#.\]NO'\Z*AG2?9B*%G33@\8ZNTPEDI!B;^QY &ZLBDM&H([/#CCY^
M^GAM=HY33O=<ZVO@QN&,CYW2Y,ETI97$OS;0-D(7$U8YN4J+R&,..C&XXCGW
MH#V4+?="Y"9=FZ-R4S](CV24TX8T_C>!_P4F^AS,^SC^>@+]&($! R^<&4ZV
M#IK0#+\)A)MI1; 8X2C.TTR^DINF'I!>]U\Q[V/> <]RD7.L9T.I%Q1+E6^3
M*H42IN(1AVV$3\Z/T1)A P12F200E5/J\/"[B%:A%L0]G0@9Q7T_"%^,W$F5
M8"Y7"2M"[[43A.3Y&#MP2IZTHFE<P.>O7]J_7[=OY#3IKU_^Q%\V.[=@_D*T
MY%YK+TXRAVB"7<835"CB(MRT@ Z3.8O<O@=92VTUE%H+1$_(BK@[60=D);.!
M;)SM[ ^HLB69!PDL>)%$VV#GPL(#B1+A?7J-:3!JHY?S1-)<#POLQ@']'1@>
MGR6N':5OD(T3<M6*?J.-O0F8Y^KP;]AKWW$>I;1U A4G!]PN[3]<GO#2^%P;
M/D]3"),8I1;>I]#Z9**;V%H>1[ 2>= \H:=>BE23I,47S]A,)I/A],M$^(S*
M_KB<L?GD##)-2,\DI/$TU6A"H\@^<3M5^IE86"/"./5M\1ZCNL#=Y?%)-KX'
MCEU?EI B48(N</VDSHRH=#2N-;'A:'*6JO (D:+C3C+@PQ\/?_'LY-?1-+OD
M<(20M>^$9PW9T=F7]K$6-!N:PY/,."0$CJ.&-#4=VW'1=4\/?\.1NXQ&[A9D
MEYE(37XKS%%%X =@GYGM6R+BCV"[=-4QW>/J6K@=9,B](YOBDB(-UY?3U*1=
M@](%J"7&2G\T3K!T%5[4AY?2O#%+R3F@L__2K$/9/1Q']"Y:R2?#/ 5;)DWB
MQVI*<-QQG; G5=M&L$3O>4?#5*T5" 9-P<^XZVC;-#-O;&H.ROC^A[LQ.*GP
MPCMV!!0&&@A(A]K^RBU=T+?^ E02\$41 H^2$4&.*-C_?#R$F^3 XQ@Q&&OH
MS#N*8919")W'8@32)NR+?@?^*Y@8 !MC0X_,-8!&D-)")9,-=G1S>]:^,FAP
M8TH86%P6^Q>QO!VMF6@Z \V.^J?75Z?SSS%+12;/J>C/E6KN!15@.6 >9)-*
MM:Q5[.;99++C#8".3.'ZH(62WF_>[6*=Z7!AS6M"Q\4Q)R7<DK#(T=4-V$P4
MG"4BWVJUQ?9HUFCE]12=+),L2?)1-'CR2)U69716Y?AH$9SB.G2CGN-S@"3.
M$\,FHMOV,5B&XW8OU>'-Z.A>O$4]AN*^"S?!IVM N-=?;FO'XS-XG@@<RZ'T
MB8$X;R%J<G8P=&5OTVW[ZKCHQ=CTE0IB9?2T,EV4LR]%.4;&BW(<H$5X&P_"
MG$I4VL8N)"I\>+&?W1X$CDN&86$RRG'J]Y,8S-'9Z3&[ S&(EF2?!]^EFE>M
MNO(H%7*:WY_]?O;EVQHWUZ"%KK"]&=D6^8-WQ4JIB8^#@T^SOA4E))/+$1M&
MH[IU9+SYE1VA7G)4G=/8&7Q_Q5JUUK%T0Q)Z1ZUR<_GY_/K\N>FS X?L<4D1
M)#I#=%(\UG[,A^QXRK-J%S\[+;'4XZ/+ON<.YP>(5!\CQH"LGN/:@5!QZP$/
M_,<AFB3,\_$X#:Q+PV@U9KW <, QF4=7%[\1W@,>B +#WK)BU*,XDX>\UO'1
M'N%!X#]@&[0?V"* !2X\5Y8BJ%&DSI7]6KH!6,BC7ZV0?<:X&=@:;1QHKYJC
M4S%/N;O466HZ\KV)E!C0!M")Z@2C(Y#">("%!:.91/*X!=ZAN4(X_!^/%T@F
MC8_PBNAJ?_GWV;?SVW:!Q2&)9B]]J 450N(1TA@(Q9!I,!+9-,)+Q=F3E[ C
M%$0U++T DXOU[\C0[G\^3D]5I/#K &QKN0\1CD[G_2WN.P'?LJ@BB.=&5,G2
MC2-NPUKZ)*KD@<D) F16(CG2*O$O;(:3Y %1$L*%Q<>'8+NU%'%.-)96R6V#
M'@_ZW/*_PY(BE ='5[\?C\_=*#!Y_J&OIMDK)Q[[[7]/OS9 XM19C^S+!F#F
M>JU:F"<4IG3A[=GG]G4[;ZR[F7S(4L(Y O(5P#_$NY.M>T^5)1BZ#W?]14E=
M1];ZX]&<SDRJ4#)12GDM.^();?!*<P5N.?OS\UGN>&4G:J[K.AV06&(0'4^I
M-H+A['%:GAB?^H@1(]HI^9[)6:!WPE,GF<J!S8]X?-P3'+:+GKD=I&<GS@9"
MX,AY ZJD3JCR:=?E'3](MS9C.NI_ :S6DA-G,K?/ZXGAWA-IU9FI[*O#XO>A
M_\#9[T[@+#DB-G.P2(^(G( $CHJD$>9X*-QWSW\ RRY,QD:N#I4K]( ]^AU\
MR1P!1B795]_I_PC/\H,<[5!Z!&1NJ$DD=,(N<+2-M?%TFFZ[T_GFB ([]ZP<
M[4S9I,NW]F_X9 BNYY7T;$2,*I!=?,O1/I4F7+;+:ZGU_*E]NF'N<*IB;LO)
MU16/SOKVND!_._:_WC@=JU*NU"NM>MDVJR8'5=&M\5I%5'FG;'9%_?^,^IO7
M?^NEUUYIFN@4H$X!/KE2F0(T,YL"I$5>^%[Q4[M]Q3Z"M^=96/+TA::$BL4I
MP3XE\XN*G.=[TUOUG<\]&5OWQ$.(0Z%PH&D!'!L/,$"9!#S5;%ROCN$]5:&
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M3_.R" 7*&R2R(!VGP)FZ<'E4DNF*.XZC>(*.$R4EFP,ZIMG"OZ?._H1=C28
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MS8A;R-&C43"#2%H2DK^<<!PG^OF'6NN$E*>,M[C2" I$XG][_OC]*L7@#:7
MDTW:LQITEFGY%-M*K>_-,.YHDO_8^5:Y"K(%^1R9E[+_2#@&_&&LVPJC$@IE
MU(^J;'V/3 $>S+4* Z4I'55J[>/<TY2WJ"YBL>CII)$Q4I-DS25QS,1D1!]3
MZJ^T(3:(<<P'%<\D!1[*GG80DD!;WIT2UK&J'!L+7IH!,U;[DVX.'VN\\4 #
ME6>?V'%2*$*V+%6PHH!&*G!YJ(KW$]&:MCB6*.&1SB*_)/& )XROJ8CI,C6,
MWI8TD:A\:*R*$]46R. X^FF36JXP_B9JK92QK\KXI*>2% :F?%K**B6ZDHKK
M1N-9E)\PY[6H="5PY'+L ADMJ(TFZ)K*:E#@V_X#GDHU[.!W(VY])P69"D.&
M,@@[I-NM7H*[B3+G\>?#84B]*1)-5/KA]Y/B#SH_P99),2>B0]-&7AI:6^AH
M)#ZH^DSROL1@P^G3$AU VK!8#! (%"GW/FI/5RP*?( ,B/L=6:\OK;DI'YJ^
M,(:^>H4G[D@I8T0M]38J!H/54C!(UM9;PL');>._@MRQ>HZX3QQ[X=T[@:\,
M;A07EI/$7L@25TXMNINR\.FV)]))@_'I17V:WBUCX9)H90^+Q\%Z1FGCA#R,
MQK&*F4W,TGV:V#\MC)X15/H<^7TX\F]D^%_*YMFW3T$YG6"4BTN>":1C)?EU
MD@C>^^H(E@\.'LBD#ENR!4@'##1A\Q22%;FX4V%4$'I3-P1""3PQ,F-I'#50
M$YG;*7:A8A]JU:*.(R)AE:0B00[L!0N6IJI,%HN@G\J$=_D]R CUDEBZUWC)
M===2XKIR(Z\\O^)53VTGC_K##S]L;C^[**4XO;RX;9_>@IG3/$E24[<]/PZ1
M?B[Y]\4MI3M>^+_QO$*+L_9W?S#DL.IFN5:L5LO%6L,TV!':-7SQ<1*[KDL,
M0.C:[,;W[63AC:)1KI<Q-:_Z;!8O/AO.V3/&!K3>:(\N1QY=;6EYV[I7LJ!O
M@?+/5/&Q)8C,7\<I&!5^$J"^F:CR@L6A0U6DEI"=+O+HW!N5?V/%"3FT8,@4
MPQYJ>31)9Z7)5A?XU>,QF"+"/EZU>KPY:5@\5]??.EC"?P%>];4/QMR"Y;=6
MG/-GU,LG*Z[;6+!N>1#62!;CX.(B>6F#4+Q+?C@!PWC@\N$['.4%RZ"'3B8_
M,*>^C+XG+RL!V6B5ZHTFRL@(A%]D)Q]6XK-$XO-M9,]>:U1+%0J<S+]<+AD+
MKRU[K5$NU:N5%[UV^;6&T=C$8IMF<]77 O)"<(+_]:;R)KDO0:/G8]%?%NY\
M2W00+'I$C91\9PX>V10%XY3)&8+S!^NQEYI/,6!Y#@-.[[RURC8D(VYM([-G
M,,O"91R& .Y<U MQTK"PT3BA,R!9Q2@LW&$VJ4!*G P1PG@G2L!B32YL1)T@
MDRSJV52RR8W.)Q0<V+"N;99QD\MI90_ 96Z<>;+/D&N39D^["P3V9)H 10^V
M2*[KINP5WI-WTF'XWT:I4<L>%5VEBPZFJ6C.;LIL!_IIQ;W\N,KZT^L.\.$,
M++Q6:%;K\]7K$H)ZQE9>P,X:]]O"?:-B[ CW6JYN#*V7E.=-.IH6JF=S[M;F
M,EI6"-:LM3(FJO(,S5JYH9G_Y<QOM++'^G+8US-8O\.M[W<T*Z2H5M:E_SM9
MV3/,-(G7"T:YMI3(7P^ G0F:?4&166DN1]%N,)%9(365#FX1G63&8=8^>N[#
M.Y>C%OAD2O&J@9[-T(DFA2E22"4A)\\$JZ4<DN1XM-;:3D=;C7I.L9\2JV\G
MPCJRHF /K&:CT##+V@M9(SQK=1V$V+L@Q/6"(?C[%(XP"N7:<M-5BX+GP+.U
ML_!.[@1!]A:<ESOW1L+>"->E"13R+%!9^<_MON-AJQ75!.^7L#6UL%TO/,U=
MP5-+A<TF?_:*[ZN:Z]<'S2.C?*S9?;_2/?Y,N&Z5Q,]>) ^J!:-9S6+RX.#2
M.)5"0Z=Q=!I'IW&RHQW&:1R'.M;VRBHLM,Q=18WWT2XT"[7RKK(:F>7[S4CH
MG=^:67CG5<[*DX]E5_"1LL&/=<I\J\&8[)'%.;9(X>%.BB(*S!-[E?XZJE4K
MVP\F[*/V/3);-1V6V1?&GZ\/]H[]S4*YOCSVHH7 \\1I1<=F=7ADY_ _%+-=
MC?'IB*X\?9)^B_CC?K5,50K5JJFE]!H#3_7&\HX2+:MUH$1+W 4-_WBNKQIS
MO:\2MU[6@>DURMN6K@G5EG$VX'\H<OI"1 M2AJM*#SV9X[6QE68U:UI$XWY;
M'D:UL:N)/)F5I!O7>16 H^W'.*MU:TKO==_,+*YRJO7.>. Y>*#,  ^AQ@'*
M.H6KZ^G?\]"QM!FTFX772I6LQ2XUZK=D 9?JVO'?.VGZP<%S1VPM3W<E3W?6
M\J?EZ<[EJ>[VU&FK/.BOK"FM_] OPBYR=08I.8<ABT-AXWFDL#(\\34YL5EH
M/U);/JOYD7E.S-4JNOAOC=#<69>[YOEM>SNYIM,GFGPUUS\+FC4]^6Z"Z]_2
MP7>_YO_H4]-\\ZL^^C0_1Y_6,W7T:79./GW/73H1_:8G\"3QC)UYNNAPTT7T
MO]VS.%NM4M6H(=,^]RS.>K74,EL++[_X>,M:J?;"4S.77ZM5:IM9[&HP6-%@
M?(:O/,=FR,J1=\\Y-'*_=OY!6*+?$<',YM>'_STX#U$?'_F*XR.S2DE;/JXV
M=6SW>J7,\PEO+D:,^;[>3F/'\R'9#D.PFUY"8SO?T(+I_G$0 (DR3AO+8&1[
M;Z)'ISSL%9@%_S+Q5^S<<Q?@'M*47S!&OPMES HK#L"WU2=H[JS#<I<G&.BT
M^HY'UA<J3QPPM@[<[XU,NPVX+5@ ACS(,Q!?X=Y-Q< S5;-VGFZ^X5FK5S2#
MK3[4X!ZL!#^88P_DFPK*1M94;)[A62VT*IL?][@W7"4G.ED3KL\^L9=9J+1V
M-=1B']D+X-G<?)Y\KX;8/YNY]F-L>K5::)27VS=Z@OV6F-8L&,WEIOO&43&_
M,-FHY:XR.=]!SJL S]2(A@4V<#D*)<^F&!R=8+B'+FNUKD\T72L\S4;&M'_6
M..S<B[AWYV $6VK\O>,JHP9&]>8C%X?#5D:]4&YFS6G-&E]]\GW[P7'=/>.D
M6D5'?]8+4'/SW=7YYB09\_%\;W_#/HU"O:(UU#H-O^86IA7FFZUDM&<^+ZTE
MG)#QC/;JF\LBA3>;A8:YW ;+6+A*TU36::I>*QA/G.6VJ[B;>5!CYM9<:KE1
M4II?;?G9X1W'I6HXBMG=1+[UO>>[ (GP'^SLK]B)AGM8B^F.MZT+,C<'[K9E
M^3&68 [XD&HOD<2X906QL-,XT(68.W)K*X5*,VMQ HW\+2&_6BBW-E]XMS?"
M+-$= S](!M>XOG=7C$309[;H[%4LOJEGE:QU0'6MM7DQNY?5+4NLA+VMJP#)
M;!K+J\LR%C/87U34"O7F\M2T+G$YC!*7SWNK[.OE0B-S_5AY!FBE4:C4-F]
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MIF*9^'&B3P+3<T&%YWWW\#<"#X*NT6=VVP'MZZU:6DZW;U7+-:D6/(2PJN5
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MRN1_C$0PA_\F\31\_7]02P$"% ,4    " !\@9M6,.#R?*$@  !;U0  $0
M            @ $     86UG;BTR,#(S,#0R-RYH=&U02P$"% ,4    " !\
M@9M6,-C>^U@#   '#   $0              @ '0(   86UG;BTR,#(S,#0R
M-RYX<V102P$"% ,4    " !\@9M6X7XH=#@)  "70P  %0
M@ %7)   86UG;BTR,#(S,#0R-U]D968N>&UL4$L! A0#%     @ ?(&;5LM.
MOSL:#@  !8,  !4              ( !PBT  &%M9VXM,C R,S T,C=?;&%B
M+GAM;%!+ 0(4 Q0    ( 'R!FU8S+F4)M@@  +U$   5              "
M 0\\  !A;6=N+3(P,C,P-#(W7W!R92YX;6Q02P$"% ,4    " !\@9M6$)C3
M 'ET   "2@< 'P              @ 'X1   86UG;BTR,#(S,S,Q96%R;FEN
C9W-R96QE87-E+FAT;5!+!08     !@ & )0!  "NN0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
